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Abstract: 
We examined the associations between changes in dietary inflammatory potential 
and risk of colorectal cancer (CRC) in 87,042 postmenopausal women recruited from 
1993-1998 into the Women’s Health Initiative. Food frequency questionnaire data were 
used to compute patterns of change in dietary inflammatory index (DII) scores and 
cumulative average DII scores over 3 years. Cox regression models were used to estimate 
hazard ratios for CRC risk.  After a median 16.2 years follow-up, 1,038 CRC cases were 
diagnosed. DII changes were not substantially associated with overall CRC, but proximal 
colon cancer risk was higher in the pro-inflammatory change DII compared to the anti-
inflammatory stable DII groups (hazard ratio, 1.32; 95% confidence interval, 1.01, 1.74). 
Among non-users of nonsteroidal anti-inflammatory drugs (NSAID) (Pinteraction=0.055) 
the pro-inflammatory stable DII group was at increased risk of overall CRC and proximal 
colon cancer. Also among non-users of NSAID, risks of overall CRC, colon cancer, and 
proximal colon cancer were higher in the highest quintile compared to the lowest 
cumulative average DII quintile (65%, 61%, and 91% increased risk, respectively). 
Dietary changes towards, or a history of, pro-inflammatory diets are associated with an 
elevated risk of colon cancer, particularly for proximal colon cancer and among non-
users of NSAID.   
Key words: colorectal cancer, dietary patterns, Women’s Health Initiative, inflammation  
List of abbreviations 
CRC  Colorectal cancer 
DII  Dietary inflammatory index 
DM  WHI Dietary Modification Trial 
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FFQ  Food frequency questionnaire 
NSAID  Non-steroidal anti-inflammatory drugs  
OS  WHI Observational Study 
PA  Physical activity 
WHI  Women’s Health Initiative 
INTRODUCTION 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in 
American women after lung and breast cancers (1). The etiology of CRC involves a 
complex interaction of cellular and molecular processes with environmental factors 
(including dietary factors). Diet may thus be a crucial modifiable factor affecting CRC 
development. Dietary patterns simultaneously take into account many aspects of diet and 
provide a more comprehensive assessment of exposure than would individual foods or 
nutrients. Dietary patterns may therefore be more predictive of disease processes and 
outcomes than the evaluation of single nutrients or foods, given that nutrients and foods 
are consumed in combination (2-4). Most dietary patterns derived through data-driven 
approaches or indices created from dietary recommendations (e.g., Healthy Eating 
Index), research findings [e.g., Dietary Approaches to Stop Hypertension], or 
culinary/foodway traditions (e.g., Mediterranean diet) have been shown to be associated 
with CRC risk (5-9), and these findings often vary by anatomic subsite of CRC. 
Modifying or improving dietary behaviors may represent an important CRC public health 
prevention strategy. While the Women’s Health Initiative (WHI) reported no effect of a 
low-fat dietary pattern intervention on CRC (10-12), analyses of the WHI Observational 
Study reported significantly lower CRC risk among individuals adhering to the American 
Cancer Society’s nutrition and physical activity guidelines (13).  
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Given the role of chronic inflammation in carcinogenesis (14, 15), dietary patterns 
associated with inflammation may influence CRC risk. Indeed, we previously reported 
that a more pro-inflammatory diet, as measured by the dietary inflammatory index (DII) 
(16-19) calculated using data from a single baseline food frequency questionnaire, was 
associated with higher risk of CRC after an average 11.3 years of follow-up in the WHI 
(20). In addition, intake of unhealthy diets may influence CRC risk when consumed over 
long periods of time (21). In a previous study using data from the WHI Observational 
Study (OS) and Dietary Modification (DM) Trial, we found modest decreases in DII 
scores over time (22). Therefore, changes in dietary behavior or the cumulative history of 
diet over time may be more predictive of CRC risk; compared to diet assessed at one time 
point. In the current study, we used DII scores to construct patterns of change over time 
in dietary inflammatory potential, as well as the cumulative average dietary inflammatory 
potential, and evaluated the association of both exposures with CRC risk. . 
METHODS 
Study population 
The WHI was designed to address the major causes of morbidity and mortality 
among postmenopausal women. The design of the WHI has been described previously 
(23). Briefly, WHI investigators enrolled 161,808 postmenopausal women 50 to 79 years 
old with a predicted >3 year survival, in 40 sites in the United States between 1993 and 
1998. Subjects were enrolled into the OS (n= 93,676) or one or more of four Clinical 
Trial groups, that included the DM with 29,294 women randomly assigned to a usual-diet 
comparison group and 19,541 women assigned to an intervention group. The intervention 
set a goal of 20% of energy intake as fat with increased intake of vegetables, fruits, and 
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whole grains. Women who proved to be ineligible for, or who were unwilling to enroll in 
the Clinical Trial components were invited to be part of the prospective cohort of women 
in the OS (23). Follow-up for the WHI is ongoing, and we used data from women with 
follow-up until August 29, 2014 for this investigation. The WHI protocol was approved 
by the institutional review boards at the Clinical Coordinating Center at the Fred 
Hutchinson Cancer Research Center (Seattle, WA) and at each of the 40 Clinical Centers 
(23).  
Diet assessment 
During screening for the WHI, all participants completed a standardized self-
administered 122-item food frequency questionnaire (FFQ) developed for the WHI to 
estimate average daily nutrient intake over the previous three-month period. This served 
as the baseline measure. Follow-up measures included: an FFQ completed by all DM 
participants at Year 1; an FFQ completed annually from year 2 until study end 
(approximately fourteen years) in a third of DM participants randomly selected each year; 
and an FFQ completed at Year 3 for ≈90% of OS participants. There was an average of 
two FFQs per participant in the OS and three FFQs per participant in the DM. Therefore 
to maximize the number of DM participants with an FFQ at one time point (other than 
year 1), we created a composite FFQ for Year 3 that included an average of FFQs in 
Years 2, 3 and 4. We did not use FFQs from Year 4 onwards because the sample sizes of 
DM participants with FFQs became progressively smaller. Secondly, we did not include 
baseline FFQ data for DM participants in the analyses due to the upward bias in baseline 
mean percent energy from fat as a result of the >32% energy from fat eligibility criterion 
(24-26). For the current study, we included FFQs from the OS and DM control group but 
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not from the DM intervention group because the intervention group participants were 
actively undergoing dietary changes while the control group participants were asked to 
follow their usual diets (26-28).  
FFQ data were considered complete if all adjustment questions, all summary 
questions, 90% of the foods, and at least one-half of every food group section was 
completed (23, 29). The nutrient database, linked to the University of Minnesota 
Nutrition Data System for Research
®
 (30), is based on the US Department of Agriculture 
Standard Reference Releases and manufacturer information. The WHI FFQ has produced 
results comparable to those from four 24-hour dietary recall interviews and four days of 
food diaries recorded within the WHI (27). 
The dietary inflammatory index (DII) 
Details of the development (16) and construct validation (17-19) of the DII have 
been described. A summary of the steps taken to create the DII are provided in Web 
Figure 1 (16). An extensive literature search was performed to identify articles published 
in peer-reviewed journals reporting on the association between dietary factors and six 
inflammation markers [interleukin (IL)-1β, IL-4, IL-6, IL-10, tumor necrosis factor alpha, 
and C-reactive protein]. A total of 1,943 eligible articles published through 2010 were 
indexed and scored to derive component-specific inflammatory effect scores. In the 
process of reading and scoring these articles a total of 45 specific foods and nutrients 
(components of the DII) were identified.   
Actual dietary intake data derived from the WHI FFQ were standardized to a 
representative global diet database constructed based on 11 datasets from diverse 
populations in different parts of the world. The standardized dietary intake data were then 
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multiplied by the literature-derived inflammatory effect scores for each DII component, 
and summed across all components, to obtain the overall DII (16). The DII score 
characterizes an individual’s diet on a continuum from maximally anti-inflammatory to 
maximally pro-inflammatory, with a higher DII score indicating a more pro-
inflammatory diet and a lower (i.e., more negative) DII score indicating a more anti-
inflammatory diet. In the WHI FFQ, 32 of the 45 original DII components were available 
for inclusion in the overall DII score (see Table 1 footnote for the list of all 45 DII 
components).  
Outcomes assessment 
The outcome for these analyses was incident CRC, including cancers of the colon 
(proximal colon, distal colon) and rectum (rectum and rectosigmoid).  Reported CRC was 
verified by centrally trained physician adjudicators after review of medical records and 
pathology reports (31). Proximal colon cancers were defined as cancers of the cecum, 
ascending colon, right colon, hepatic flexure of colon, and transverse colon (International 
Classification of Diseases=C18.0, C18.2-18.4), and distal colon cancers were defined as 
cancers of the splenic flexure of colon, descending colon, left colon and sigmoid colon 
(International Classification of Diseases=C18.5-18.7). Survival time was defined as days 
from enrollment or randomization until CRC diagnosis while censoring time was defined 
as days from enrollment or randomization until death or last contact occurring on or 
before August 29, 2014, in participants without CRC. 
Statistical analysis 
We utilized data from 122,970 women participating in the WHI OS and DM 
control group. Exclusion criteria included: women with CRC at baseline or missing CRC 
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status at baseline (n=2,118), women reporting any cancer at or prior to baseline 
(n=9,232), any cancer (including CRC) diagnosed within three years from baseline 
during the follow-up period (n=3,348), CRCs diagnosed as second primaries during 
follow-up (n=66), women with reported total energy intake values judged to be 
implausible (≤600 kcal/day or ≥5000 kcal/day) (n=4,106) or extreme body mass index 
values (<15kg/m
2
 or > 50kg/m
2
) (n=588), as well as participants with single FFQs 
(n=13,517). Frequencies and percentages were computed to describe the distribution of 
covariates across quintiles of cumulative average DII assessed from baseline to Year 3. 
The differences in DII scores between baseline to Year 3 in the OS and from Year 
1 to composite Year 3 in the DM control group are referred to as “change in DII,”  while 
the cumulative average DII score in these time points is referred as “cumulative average 
DII.” To determine the role of patterns of change in the inflammatory potential of diet 
over time in CRC risk, we calculated the DII and categorized it into quintiles (Q) at both 
time points (32). We then further categorized the changes in the inflammatory potential 
of diet based on quintile differences between the first and second time points, as follows:  
1. Anti-inflammatory stable: Q1 or Q2 at both time points or change from Q3 to Q2;  
2. Anti-inflammatory change: changes ≤ -2Q;  
3. Neutral inflammation stable: changes from Q2 to Q3, Q4 to Q3 or stable at Q3 at 
both time points;  
4. Pro-inflammatory change: changes ≥ 2Q;  
5. Pro-inflammatory stable: Q4 or Q5 at either time points, or change from Q3 to 
Q4.  
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The names given to these categories of DII changes were meant to be qualitative 
only. We decided to use quintiles for constructing this 5-level exposure variable in order 
to maximize the contrast between DII change scores, while maintaining a sufficiently 
large sample size within each quantile of DII change to observe an association.  
To determine the role of cumulative history of the inflammatory potential of diet 
in CRC risk over time, we estimated hazard ratios (HR) for newly incident overall CRC, 
colon (proximal/distal) cancer, and rectal cancer, using multivariable-adjusted Cox 
regression models by quintiles of cumulative average DII scores (33) and by patterns of 
DII changes adjusted for multiple covariates. We excluded all CRC cases diagnosed prior 
to Year 3 to establish appropriate temporality between exposure and outcome. .  
Potential baseline confounders that changed HRs by >10% were retained in the 
final model. These were: age group (years) (50-59, 60-69, 70-79); race/ethnicity 
[European American, African American, Hispanic, Asian or Pacific Islander, and other 
race groups (other), missing]; educational levels (less than high school, some high school 
/General Educational Development, at least some college/graduate education, missing); 
smoking status (current, past, never, missing); body mass index [weight(kg)/height(m)
2
, 
≤24.9kg/m2, 25.0-29.9 kg/m2, and ≥30kg/m2, missing]; physical activity (PA) was 
categorized based on public health recommendations (34), as meeting or not meeting PA 
recommendations (≥150 minutes/week of moderate intensity PA or ≥75 minutes/week of 
vigorous intensity PA versus <150 minutes/week of moderate intensity PA or <75 
minutes/week of vigorous intensity PA, respectively), or missing PA; (3) history of 
diabetes (yes, no, missing), hypertension (yes, no, missing), arthritis (yes, no, missing); 
regular use of non-steroidal anti-inflammatory drugs (NSAID) (yes, no, missing); 
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category and duration of estrogen use and category and duration of combined estrogen 
and progesterone use both categorized into five groups (none, ≤4.9y, 5.0-10.0y, 10.1-
14.9y, and ≥15.0y). NSAID included aspirin and non-aspirin NSAID (non-aspirin 
salicylates, ibuprofen, indomethacin, naproxen, piroxicam, celecoxib, and others). 
Regular NSAID use was defined as use of an NSAID or acetaminophen at least two times 
in each of the two weeks preceding the interview. Details on medication use were 
collected from baseline questionnaires and were updated at Year 3 clinic visit for the OS 
and at Years 1, 3, 6, and 9 for DM control group (35, 36). For the current analyses, we 
used only baseline NSAID data because of the higher amount of missing data at Year 3 
(~20%) compared to baseline (~5%). Data on potential confounders were collected 
through self-administration of standardized questionnaires on demographics, medical 
history, and lifestyle factors. Certified staff performed physical measurements, including 
blood pressure, height and weight (23). For missing data, we included a separate missing 
category for categorical variables and assigned the median for continuous variables. Data 
from a total of 87,042 participants were therefore available for the final analyses (76.1% 
in the OS and 23.9% in the DM control group). 
Each covariate in the final models for both patterns of change in DII and 
cumulative average DII was tested for adherence to the proportional hazards assumption 
using cumulative sums of Martingale-based residuals. None of the covariates violated the 
proportional hazards assumption. We investigated effect modification of the association 
between changes in the DII and cumulative average DII and CRC incidence according to 
education, body mass index and NSAID use, by including two-way cross-product terms 
for these covariates in the models, and assessed significant effect modification at p <0.10.  
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Confidence intervals that did not include 1 were considered to indicate statistically 
significant results (i.e., at the nominal a=0.05). Statistical analyses were conducted using 
SAS
®
 version 9.3 (SAS Institute, Cary, NC), and all tests were two-sided. 
RESULTS 
During a median 16.2 years of follow-up, 1,038 incident CRC cases (859 colon 
and 183 rectal) were identified. In the first 3 years of follow-up, 29.7% of participants 
were classified as having an anti-inflammatory stable dietary pattern, 12.3% had anti-
inflammatory dietary changes, 14.4% were in the neutral inflammation stable category, 
11.3% experienced pro-inflammatory changes, while 32.3% were in the pro-
inflammatory stable category. Table 1 shows the distribution of participants’ baseline 
characteristics across patterns of DII change. In the pro-inflammatory stable category, 
there was a higher proportion of African Americans (10.7%) or Hispanics (4.8%), 
participants with < high school education (5.9%), current smokers (7.7%), and obese 
participants (32.7%), and participants not meeting physical activity recommendations 
(51.8%) compared to the anti-inflammatory stable category (Table 1). 
The cumulative average (SD) DII was -1.18 (2.33), ranging from a minimum of -
6.62 to a maximum of +5.39. Table 2 shows the distribution of participants’ baseline 
characteristics in quintiles of cumulative average DII. There was a higher proportion of 
African Americans (13.9%) or Hispanics (5.7%), participants with < high school 
education (7.3%), current smokers (9.1%), and obese participants (35.5%), participants 
not meeting physical activity recommendations (56.1%) in the highest compared to the 
lowest cumulative average DII quintile (Table 2). Participants in quintile 1, with the 
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lowest DII scores also had high intakes of fruits, vegetables, nuts and wholegrains (Web 
Table 1). 
Table 3 presents the results of the associations between patterns of change in the 
inflammatory potential of diet and CRC risk for all participants and separately by 
category of NSAID use. There was no substantial association between changes in DII and 
overall CRC risk when all participants were considered. However, there were significant 
differences in the association of changes in DII and CRC risk by category of NSAID use 
(Pinteraction=0.055). Among non-users of NSAID, there was significantly higher risk of 
CRC (HR, 1.33; 95% confidence interval (CI), 1.02, 1.73), especially proximal colon 
cancer (HR, 1.42; 95%CI, 1.01, 2.03), in women classified in the pro-inflammatory stable 
category compared to women in the anti-inflammatory stable category. There were no 
significant associations among regular users of NSAID (Table 3). The age-adjusted 
associations are presented in Web Table 2. 
Table 4 presents HRs of the association between cumulative average DII and 
CRC risk. Comparing participants in the highest quintile to those in the lowest quintile of 
cumulative average DII, there was a higher risk of CRC overall (HR, 1.33; 95%CI, 1.08, 
1.64; Ptrend=0.08). Risk was higher among women with proximal colon cancer but not 
among women with distal colon cancer or rectal cancer. The term for the interaction 
between cumulative average DII and NSAID use was not statistically significant 
(Pinteraction=0.43); however, based on our findings using the DII change variable, we 
stratified models by category of NSAID use. Higher risk of CRC overall and by anatomic 
subsite was limited to non-users of NSAID. For example, among non-users of NSAID, 
there was a 65% higher risk of CRC (95%CI, 1.19, 2.29; Ptrend=0.01), and 61% higher 
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risk of colon cancer (95%CI, 1.12, 2.29; Ptrend=0.02). Risk was especially pronounced for 
proximal colon cancer (HR, 1.91; 95%CI, 1.24, 2.96; Ptrend=0.006). Among regular users 
of NSAID, there was no increase in risk for higher cumulative average DII quintiles 
(Table 4). The age-adjusted associations are presented in Web Table 3. 
DISCUSSION 
In this large prospective study, we found that dietary changes towards more pro-
inflammatory diets and a history of higher cumulative average dietary inflammatory 
potential assessed over a 3-year period were associated with a higher risk of developing 
CRC, especially proximal colon cancer, after a median 16.2 years of follow-up. The 
higher risk was mainly limited to non-users of NSAID. To the best of our knowledge, this 
is the first study to characterize the association between changes over time and the 
cumulative history in the inflammatory potential of diet, and risk of overall CRC and by 
anatomic subsite in categories of NSAID use. There was no statistically significant 
association between changes in DII over time or cumulative average DII and distal colon 
cancer or rectal cancer.  
Our results from models including all participants are generally similar to 
previous findings from prospective studies of diet quality and CRC risk (5, 37, 38), where 
poorer diet quality (here characterized by higher, more pro-inflammatory DII scores), has 
been associated with higher CRC risk. We previously examined the association between 
baseline DII and CRC risk in the WHI and results were similar to the current study’s 
findings, though smaller in magnitude. In that study, we found a 22% higher risk of 
overall CRC (HR, 1.22; 95%CI, 1.05, 1.43; Ptrend=0.04), which was limited to the 
proximal colon (HR, 1.35; 95%CI, 1.05, 1.67; Ptrend=0.01) (20). Cumulating dietary 
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measures over time could reduce within-subject variation and improve ability to detect 
elevated risk.   
The differences in CRC risk estimates between NSAID use categories were 
clinically meaningful. This is consistent with previous work in which we found similar 
trends in the association of a combined lifestyle index and colorectal adenomatous polyps 
(precursor lesions of CRC), by NSAID use. Higher scores (representing a healthier 
lifestyle pattern) were associated with lower odds of colorectal adenomas among non-
users of NSAID, but not among users (3). One other study examining the association 
between the DII and risk of CRC observed significantly higher risk among non-users of 
NSAID but not among users (20), while another found that higher DII scores were 
significantly associated with higher concentrations of inflammation markers only in non-
users of NSAID (18).  
The link between inflammation and CRC is supported by findings from several 
studies showing either a lower risk of CRC with regular use of NSAID (39, 40), or a 
positive association between higher concentrations of inflammation markers and higher 
CRC risk (41, 42). Other potential mechanisms through which a pro-inflammatory diet 
may increase risk of CRC include components of the metabolic syndrome, especially 
insulin resistance or glucose intolerance (43, 44), and influences on the microbiota. A 
high and sustained pro-inflammatory potential of the diet may compromise the host-
microbiota mutualism, favoring the proliferation of toxic bacteria that have been 
suggested to promote colorectal carcinogenesis (45).  
It is interesting to note that intakes of major food groups deemed healthy (e.g., 
vegetables, fruits, whole grains) were higher among DII quintile 1 and lower among DII 
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quintile 5, while less healthy food groups (e.g., red meat) did not increase consistently 
across the five quintiles (Web Table 1). This suggests that it may be the absence of 
certain healthy food groups, rather than excesses of unhealthy food groups that contribute 
to high DII scores in this population, though the list of unhealthy foods in Web Table 1 is 
by no means comprehensive. The DII score in this study is comprised of mostly 
macronutrients, micronutrients and phytochemicals, not foods or food groups, so DII 
scores represent a balance of a multitude of dietary factors, with the majority being anti-
inflammatory. 
Strengths of the current study include the ability to account for changes in the 
inflammatory potential of diet over time by using the DII; use of a large, well-
characterized population with a long follow-up period and sufficiently large sample size 
to allow stratification of analyses in categories of NSAID; the inclusion of women of 
diverse race/ethnic groups, and the central adjudication of CRC diagnosis. Limitations 
include known measurement error in using an FFQ for the assessment of diet and its 
inflammatory potential over time (though we use ≥2 FFQs measured several years apart). 
Though we adjusted for many potential confounders, residual or unmeasured 
confounding is still a possibility. It also is important to note that all of the DII 
components missing from the WHI FFQ (ginger, turmeric, garlic, oregano, pepper, 
rosemary, eugenol, saffron, flavan-3-ol, flavones, flavonols, flavonones, anthocyanidins) 
are anti-inflammatory. However, in the construct validation of the DII in the WHI, the 
DII computed based on the 32 components significantly predicted concentrations of 
inflammation markers (18). The -6.62 to +5.39 range of cumulative average DII in the 
current study is comparable to the range of -5.4 to +5.8 obtained in another study using 
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data from fifteen 24-hour dietary recalls with 44 of the 45 DII components (17). These 
results suggest that in Western populations the range of DII scores may be more 
dependent on the amount of foods actually consumed rather than on the number of 
components available for scoring. 
In summary, dietary changes towards the intake of more pro-inflammatory diets 
and a history of pro-inflammatory diets over a 3-year period are associated with higher 
risk of colon cancer, particularly proximal colon cancer and especially among non-users 
of NSAID. Future work may test interventions designed to reduce the inflammatory 
potential of diet as a means for colon cancer prevention, especially targeted to non-users 
of NSAID. 
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TABLES AND FIGURES 
Table 1. Frequencies (%) of participant's baseline characteristics across patterns of change in dietary inflammatory 
potential; Women's Health Initiative, 1993-2014  
  Patterns of changea in quintiles of the dietary inflammatory indexb    
Characteristic 
Anti-
inflammatory 
stable  
Anti-
inflammatory 
change 
Neutral 
inflammation 
stable 
Pro-
inflammatory 
change 
Pro-
inflammatory 
stable 
  n % n % n % n % n % 
Age groups (years)                     
<50-59 8006 30.9 3941 37.0 3869 30.9 3359 34.3 10028 35.6 
60-69 12348 47.7 4752 44.6 5695 45.5 4309 44.0 12414 44.1 
70-79 5533 21.4 1968 18.4 2953 23.6 2131 21.7 5736 20.3 
Race/ethnicity 
          
Asian or Pacific Islander 960 3.7 333 3.0 243 1.9 296 3.0 635 2.3 
African American 917 3.5 782 7.2 705 5.6 751 7.8 3025 10.7 
Hispanic/Latino 398 1.5 303 2.8 327 2.6 398 4.1 1340 4.8 
European American  23235 89.8 9033 85.6 11059 88.4 8166 83.3 22653 80.4 
Other 320 1.2 174 1.1 154 1.2 164 1.6 459 1.6 
Missing 57 0.3 36 0.3 29 0.3 24 0.2 66 0.2 
Educational level                     
< High school 508 2.0 371 3.5 458 3.7 402 4.1 1661 5.9 
Some high school/GED 11798 45.6 5538 51.9 6838 54.6 5313 54.2 16375 58.1 
Some years of 
college/graduate 
13439 51.9 4683 43.9 5136 41.0 3984 40.7 9911 35.2 
Missing 142 0.5 69 0.7 85 0.7 100 1.0 231 0.8 
Smoking status 
          
Never 13146 50.8 5330 50.0 6577 52.5 5016 51.2 14503 51.5 
Former 11691 45.2 4602 43.1 5165 41.2 4168 42.5 11307 40.1 
Current 914 3.5 660 6.2 693 5.6 514 5.6 2176 7.7 
Missing 136 0.5 69 0.7 82 0.7 71 0.7 192 0.7 
Body mass indexc                     
Normal weight (≤24.9) 10783 41.7 3957 37.1 4439 35.5 3334 34.1 9074 32.2 
Overweight (25.0-29.9) 8994 34.7 3770 35.3 4461 35.6 3474 35.4 9884 35.1 
Obese (≥30) 6110 23.6 2934 27.6 3617 28.9 2991 30.5 9220 32.7 
Physical activity, minutes/week 
         
Not meeting physical 
activity recommendations 
8492 32.8 4509 42.3 5577 44.6 4048 41.3 14599 51.8 
Meeting physical activity 
recommendations 
17365 67.1 6136 57.6 6920 55.3 5731 58.5 13505 47.9 
Missing 31 0.1 16 0.1 20 0.1 20 0.2 74 0.3 
Regular NSAID used                     
No 9875 38.2 4423 41.5 4690 37.5 3982 40.6 11901 42.2 
Yes 15063 58.2 5759 54.0 7359 58.8 5366 54.8 14410 51.1 
Missing 949 3.6 479 4.5 468 3.7 451 4.6 1867 6.7 
OR
IG
IN
AL
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
 
27 
GED=General educational development, NSAID=non-steroidal anti-inflammatory drugs; 
aThe differences in dietary inflammatory index (DII) scores from baseline to year 3 in the Observational Study and from year 1 to composite year 3 (i.e., 
years 2,3&4) in the Dietary Modification Trial control group are referred to as “change in DII.” We categorized the changes in the DII based on quintile 
(Q) differences between the first and second time points, as follows: 1) anti-inflammatory stable: Q1 or Q2 at both time points or change from Q3 to 
Q2; 2) anti-inflammatory change: changes ≤ -2Q; 3) neutral inflammation stable: changes from Q2 to Q3, Q4 to Q3 or stable at Q3 at both time 
points; 4) pro-inflammatory change: changes ≥ 2Q; and 5) pro-inflammatory stable: Q4 or Q5 at either time points, or change from Q3 to Q4; 
bDII components available in the Women’s Health Initiative (WHI) food frequency questionnaire (FFQ) were: (anti-inflammatory components): 
alcohol, beta-carotene, caffeine,  fiber, folic acid, magnesium , niacin, riboflavin, thiamin, zinc, monounsaturated fatty acid (fa) polyunsaturated fa, 
omega 3 fa, omega 6 fa, selenium, vitamins B6, A, C, D, E, onion, green/black tea, isoflavones, (pro-inflammatory components): vitamin B12, iron, 
carbohydrates, cholesterol, total energy, total fat, saturated fat, trans fat, protein. The following components, all anti-inflammatory, were not available 
in the WHI FFQ: ginger, turmeric, garlic, oregano, pepper, rosemary, eugenol, saffron, flavan-3-ol, flavones, flavonols, flavonones, anthocyanidins; 
cWeight (kg)/height (m)2 
dRegular use of NSAID was defined as use at least 2 times in each of the 2 weeks preceding the interview. 
 
 
 
Table 2. Frequencies (%) of participant's baseline characteristics across quintiles of cumulative average DII
a,b
 
(baseline
c
 and Year 3); Women's Health Initiative, 1993-2014 
Characteristic 
Quintile 1  
(-6.62, < -3.25) 
(more anti-
inflammatory) 
Quintile 2  
(-3.25,  
< -2.17) 
Quintile 3  
(-2.17,  
< -0.84) 
Quintile 4  
(< -0.84, 
0.97) 
Quintile 5  
(0.97, 5.39) 
(more pro-
inflammatory) 
  n % n % n % n % n % 
Age groups (years)                     
<50-59 5483 31.5 5368 30.8 5732 32.9 6102 35.1 6518 37.4 
60-69 8286 47.6 8063 46.3 7892 45.3 7711 44.3 7566 43.5 
70-79 3639 20.9 3977 22.9 3785 21.8 3595 20.6 3325 19.1 
Race/ethnicity 
         
 Asian or Pacific Islander 779 4.5 465 2.7 447 2.6 448 2.6 328 1.9 
African American 551 3.2 734 4.2 1038 6.0 1445 8.3 2412 13.9 
Hispanic/Latino 260 1.5 334 2.0 501 2.9 672 3.9 999 5.7 
European American  15543 89.3 15613 89.7 15127 86.9 14535 83.5 13328 76.6 
Other 238 1.3 220 1.2 245 1.4 265 1.5 300 1.7 
Missing 37 0.2 42 0.2 49 0.2 42 0.2 42 0.2 
Educational level                     
< High school 275 1.6 498 2.9 590 3.4 767 4.4 1270 7.3 
Some high school/GED 7386 42.4 8789 50.5 9338 53.6 9767 56.1 10582 60.8 
Some years of 
college/graduate 
9654 55.5 7998 45.9 7365 42.3 6733 38.7 5403 31.0 
Missing 93 0.5 123 0.7 116 0.7 141 0.8 154 0.9 
Smoking status 
         
 Never 8642 49.6 8977 51.6 9043 51.9 8986 51.6 8924 51.3 
Former 8124 46.7 7552 43.4 7294 41.9 7181 41.3 6782 39.0 
Current 550 3.2 780 4.4 950 5.5 1116 6.4 1591 9.1 
Missing 92 0.5 99 0.6 122 0.7 125 0.7 112 0.6 
Body mass indexd                     
Normal weight (≤24.9) 7670 44.1 6707 38.5 6201 35.6 5782 33.2 5227 30.0 
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Overweight (25.0-29.9) 5953 34.2 6140 35.3 6277 36.1 6216 35.7 5997 34.5 
Obese (≥30) 3785 21.7 4561 26.2 4931 28.3 5410 31.1 6185 35.5 
Physical activity, minutes/week 
        
 Not meeting physical 
activity recommendations 
4887 28.1 6818 39.2 7436 42.7 8315 47.8 9769 56.1 
Meeting physical activity 
recommendations 
12501 71.8 10571 60.7 9942 57.1 9051 52.0 7592 43.6 
Missing 20 0.1 19 0.1 31 0.2 42 0.2 48 0.3 
Regular NSAID usee                     
No 6833 39.3 6621 38.1 6835 39.3 7179 41.2 7403 42.5 
Yes 9894 56.8 10171 58.4 9813 56.4 9319 53.5 8760 50.3 
Missing 681 3.9 616 3.5 761 4.3 910 5.3 1246 7.2 
DII=dietary inflammatory index, GED=General education development, NSAID=non-steroidal anti-inflammatory drugs; 
aThe cumulative average DII was the average of the DII scores at baseline (Year 1 for the Dietary Modification Trial control group) and Year 3; 
bDII components available in the Women’s Health Initiative (WHI) food frequency questionnaire (FFQ) were: (anti-inflammatory components): 
alcohol, beta-carotene, caffeine,  fiber, folic acid, magnesium , niacin, riboflavin, thiamin, zinc, monounsaturated fatty acid (fa) polyunsaturated fa, 
omega 3 fa, omega 6 fa, selenium, vitamins B6, A, C, D, E, onion, green/black tea, isoflavones, (pro-inflammatory components): vitamin B12, iron, 
carbohydrates, cholesterol, total energy, total fat, saturated fat, trans fat, protein. The following components, all anti-inflammatory, were not available 
in the WHI FFQ: ginger, turmeric, garlic, oregano, pepper, rosemary, eugenol, saffron, flavan-3-ol, flavones, flavonols, flavonones, anthocyanidins; 
cYear 1 and composite Year 3 for the Dietary Modification Trial control group; 
dWeight (kg)/height (m)2 
eRegular use of NSAID was defined as use at least 2 times in each of the 2 weeks preceding the interview. 
 
 
Table 3: Multivariable-adjusted
a
 hazards ratios of the association between patterns of change in dietary 
inflammatory potential and colorectal
2
 cancer risk stratified by NSAID use; Women's Health Initiative, 1993-2014  
  Patterns of changeb in quintiles of the dietary inflammatory index  
 Tumor locationc 
Anti-
inflammatory 
stable (Referent) 
Anti-
inflammatory 
change 
Neutral 
inflammation 
stable 
Pro-inflammatory 
change 
Pro-inflammatory 
stable 
 HR   HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
All participants 
Colorectal cancer 1.00   1.09 0.88, 1.34 1.07 0.88, 1.31 1.10 0.89, 1.37 1.06 0.90, 1.26 
Colon cancer 1.00 
 
1.11 0.88, 1.40 1.14 0.92, 1.44 1.11 0.87, 1.41 1.07 0.89, 1.29 
Proximal colon 
cancer 
1.00   1.11 0.84, 1.47 1.06 0.81, 1.39 1.32 1.01, 1.74 1.05 0.84, 1.31 
Distal colon cancer 1.00 
 
0.98 0.61, 1.58 1.42 0.95, 1.13 0.81 0.47, 1.38 1.13 0.79, 1.63 
Rectal cancer 1.00   0.98 0.60, 1.60 0.71 0.43, 1.20 1.06 0.64, 1.75 0.98 0.67, 1.44 
Non users of non-steroidal anti-inflammatory drugs 
Colorectal cancer 1.00 
 
1.09 0.77, 1.53 1.04 0.74, 1.46 1.25 0.88, 1.76 1.33 1.02, 1.73 
Colon cancer 1.00   1.05 0.72, 1.52 1.07 0.75, 1.55 1.20 0.82, 1.75 1.30 0.97, 1.75 
Proximal colon 
cancer 
1.00 
 
1.13 0.72, 1.78 0.84 0.51, 1.37 1.34 0.85, 2.11 1.42 1.01, 2.03 
Distal colon cancer 1.00   0.86 0.40, 1.87 1.79 0.98, 3.27 1.20 0.58, 2.49 1.09 0.62, 1.93 
Rectal cancer 1.00 
 
1.24 0.54, 2.81 0.76 0.29, 1.96 1.43 0.62, 3.30 1.42 0.74, 2.72 
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Regular users of non-steroidal anti-inflammatory drugs 
Colorectal cancer 1.00   1.09 0.83, 1.43 1.12 0.87, 1.43 1.08 0.81, 1.43 0.83 0.66, 1.03 
Colon cancer 1.00 
 
1.13 0.83, 1.54 1.19 0.91, 1.57 1.10 0.80 1.51 0.86 0.66, 1.11 
Proximal colon 
cancer 
1.00   1.13 0.78, 1.64 1.28 0.92, 1.77 1.40 0.98, 2.00 0.74 0.53, 1.02 
Distal colon cancer 1.00 
 
0.87 0.45, 1.69 0.97 0.55, 1.72 0.53 0.24, 1.21 1.13 0.70, 1.82 
Rectal cancer 1.00   0.96 0.52, 1.78 0.76 0.41, 1.43 1.01 0.53, 1.92 0.71 0.41, 1.21 
NSAID=non-steroidal anti-inflammatory drugs; 
aAll models were adjusted for age, race/ethnicity, educational level, smoking status, diabetes, hypertension, arthritis, regular NSAID use (except when 
stratified by NSAID use), category and duration of estrogen use, category and duration of estrogen & progesterone use, body mass index, physical 
activity and total energy intake;  
bThe differences in dietary inflammatory index (DII) scores from baseline to year 3 in the Observational Study and from year 1 to composite year 3 (i.e., 
years 2,3&4 combined) in the Dietary Modification Trial control group are referred to as “change in DII.” We categorized the changes in the DII based 
on quintile (Q) differences between the first and second time points, as follows: 1) anti-inflammatory stable: Q1 or Q2 at both time points or change 
from Q3 to Q2; 2) anti-inflammatory change: changes ≤ -2Q; 3) neutral inflammation stable: changes from Q2 to Q3, Q4 to Q3 or stable at Q3 at 
both time points; 4) pro-inflammatory change: changes ≥ 2Q; and 5) pro-inflammatory stable: Q4 or Q5 at either time points, or change from Q3 to 
Q4; 
cInternational classification of diseases (ICD)-O-2 codes used to define location of colon cancer include C18.0 (cecum), C18.2 (ascending colon, right 
colon), C18.3 (hepatic flexure of colon), C18.4 (transverse colon), C18.5 (splenic flexure of colon), C18.6 (descending colon, left colon) and  C18.7 
(sigmoid colon); rectal cancer include all rectum and rectosigmoid cases; 
 
 
 
Table 4: Multivariable-adjusted
a
 hazards ratios of the association between cumulative average dietary 
inflammatory index and colorectal cancer risk stratified by NSAID use; Women's Health Initiative, 1993-2014  
Quintiles of cumulative average dietary inflammatory index
b
 
Tumor locationc  
Quintile 1  
(more anti-
inflammatory 
diet) referent 
Quintile 2 Quintile 3 Quintile 4 
Quintile 5  
(more pro-
inflammatory 
diet) 
dPtrend 
 HR   HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 
All participants 
Colorectal 
cancer 
1.00   1.14 0.93, 1.39 1.22 1.00, 1.49 0.93 0.75, 1.15 1.33 1.08, 1.64 0.08 
Colon cancer 1.00 
 
1.15 0.92, 1.44 1.24 0.99, 1.54 0.95 0.75, 1.21 1.37 1.09, 1.73 0.06 
Proximal colon 
cancer 
1.00   1.28 0.98, 1.66 1.25 0.96, 1.64 0.96 0.72, 1.28 1.35 1.02, 1.79 0.30 
Distal colon 
cancer 
1.00 
 
0.88 0.56, 1.38 1.27 0.83, 1.93 0.88 0.55, 1.39 1.35 0.87, 2.11 0.19 
Rectal cancer 1.00   1.06 0.67, 1.69 1.14 0.72, 1.82 0.79 0.47, 1.31 1.10 0.67, 1.80 0.90 
Non users of non-steroidal anti-inflammatory drugs   
Colorectal 
cancers 
1.00 
 
1.15 0.83, 1.61 1.38  1.00, 1.89 0.97 0.69, 1.37 1.65 1.19, 2.29 0.01 
Colon cancer 1.00   1.09 0.76, 1.57 1.30 0.92, 1.85 0.99 0.69, 1.44 1.61 1.12, 2.29 0.02 
Proximal colon 
cancer 
1.00 
 
1.17 0.75, 1.83 1.34 0.87, 2.08 1.02 0.64, 1.62 1.91 1.24, 2.96 0.006 
Distal colon 
cancer 
1.00   1.11 0.57, 2.17 1.35 0.71, 2.57 0.98 0.49, 1.96 1.16 0.57, 2.35 0.88 
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30 
Rectal cancer 1.00 
 
1.37 0.60, 3.11 1.64 0.74, 3.65 0.73 0.28, 1.89 1.70 0.74, 3.90 0.53 
Regular users of non-steroidal anti-inflammatory drugs   
Colorectal 
cancer 
1.00   1.10 0.85, 1.43 1.12 0.86, 1.45 0.83 0.62, 1.11 1.07 0.80, 1.43 0.69 
Colon cancer 1.00 
 
1.17 0.88, 1.56 1.18 0.88, 1.58 0.86 0.62, 1.19 1.13 0.82, 1.56 0.86 
Proximal colon 
cancer 
1.00   1.35 0.96, 1.90 1.24 0.87, 1.76 0.87 0.59, 1.29 0.91 0.60, 1.37 0.10 
Distal colon 
cancer 
1.00 
 
0.63 0.33, 1.20 1.07 0.61, 1.89 0.69 0.36, 1.33 1.52 0.85, 2.74 0.09 
Rectal cancer 1.00   0.89 0.49, 1.59 0.95 0.53, 1.72 0.72 0.38, 1.37 0.82 0.42, 1.61 0.46 
NSAID=non-steroidal anti-inflammatory drugs; 
aAll models were adjusted for age, race/ethnicity, educational level, smoking status, diabetes, hypertension, arthritis, regular NSAID use (except when 
stratified by NSAID use), category and duration of estrogen use, category and duration of estrogen & progesterone use, body mass index, physical 
activity and total energy intake;  
bThe cumulative average dietary inflammatory index (DII) was the average of the DII scores at baseline (Year 1 for the Dietary Modification Trial 
control group) and Year 3; 
eInternational classification of diseases (ICD)-O-2 codes used to define location of colon cancer include C18.0 (cecum), C18.2 (ascending colon, right 
colon), C18.3 (hepatic flexure of colon), C18.4 (transverse colon), C18.5 (splenic flexure of colon), C18.6 (descending colon, left colon) and  C18.7 
(sigmoid colon); rectal cancer include all rectum and rectosigmoid cases; 
dThe p value for trend was obtained by assigning the median cumulative average DII for each quintile to all participants in the quintile and inserting this 
ordinal variable in the multivariable-adjusted model; 
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